Referenser

Referenser till innehållet på sidan "Fördjupad information om vaccination mot rotavirus".

1. Rotavirusinfektion i Sverige. Kunskapsunderlag 2015.
2. Velazquez FR, Matson DO, Calva JJ, Guerrero L, Morrow AL, Carter-Campbell S et al. Rotavirus Infection in Infants as Protection against Subsequent Infections. N Engl J Med 1996 Oct 3;335(14):1022-8.
3. Dennehy PH, Nelson SM, Crowley BA, Saracen CL. Detection of rotavirus RNA in hospital air samples by polymerase chain reaction (PCR) * 828. Pediatric Research Program Issue APS-SPR 1998 Apr;43(4):143.
4. Wildi-Runge S, Allemann S, Schaad UB, Heininger U. A 4-year study on clinical characteristics of children hospitalized with rotavirus gastroenteritis. Eur J Pediatr. 2009 Nov;168(11):1343-8.
5. Gleizes O, Desselberger U, Tatochenko V, Rodrigo C, Salman N, Mezner Z et al. Nosocomial Rotavirus Infection in European Countries: A Review of the Epidemiology, Severity and Economic Burden of Hospital-Acquired Rotavirus Disease. Pediatr Infect Dis J 2006 Jan;25(1):S12-S21
6. Bruijning-Verhagen P, Quach C, Bonten M. Nosocomialrotavirus infections: a meta-analysis. Pediatrics. 2012 Apr;129(4):e1011-9. doi: 10.1542/peds.2011-2779.
7. Iturriza-Gomara M, Auchterlonie IA, Zaw W, Molyneaux P, Desselberger U, Gray J. Rotavirus Gastroenteritis and Central Nervous System (CNS) Infection: Characterization of the VP7 and VP4 Genes of Rotavirus Strains Isolated from Paired Fecal and Cerebrospinal Fluid Samples from a Child with CNS Disease. J Clin Microbiol 2002 Dec 1;40(12):4797-9.
8. Johansen K, Hedlund KO, Zweygberg-Wirgart B, Bennet R. Complications attributable to rotavirus-induced diarrhoea in a Swedish paediatric population: Report from an 11-year surveillance. Scand J Infect Dis 2008 Jan 1;40(11-12):958-64.
9. Bishop RF, Barnes GL, Cipriani E, Lund JS. Clinical immunity after neonatal rotavirus infection. A prospective longitudinal study in young children. N Engl J Med 1983 Jul 14;309(2):72-6.
10. Ward RL, Bernstein DI, for the US Rotavirus Vaccine Efficacy Group. Protection against Rotavirus Disease after Natural Rotavirus Infection. J Infect Dis 1994 Apr 1;169(4):900-4.
11. Velazquez FR. Protective Effects of Natural Rotavirus Infection. The Pediatric Infectious Disease Journal 2009;28(3).
12. Hrdy DB. Epidemiology of rotaviral infection in adults. Rev Infect Dis 1987 May;9(3):461-9.
13. Liakopoulou E, Mutton K, Carrington D, Robinson S, Steward CG, Goulden NJ et al. Rotavirus as a significant cause of prolonged diarrhoeal illness and morbidity following allogeneic bone marrow transplantation. Bone Marrow Transplant 2005 Aug 22;36(8):691-4.
14. WHO position paper. Rotavirus vaccines - January 2013. Wkly Epidemiol Rec 2013 Feb 1;88(5):49-64
15. Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006 Jan 5;354(1):23-33.
16. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, Abate H, Breuer T, Clemens SC et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006 Jan 5;354(1):11-22.
17. Vesikari T, Karvonen A, Prymula R, Schuster V, Tejedor JC, Cohen R et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. The Lancet 2007 Nov 24;370(9601):1757-63.
18. Vesikari T, Karvonen A, Ferrante SA, Kuter BJ, Ciarlet M. Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine. Pediatr Infect Dis J 2010 Oct;29(10):957-63.
19. Phua KB, Lim FS, Lau YL, Nelson EA, Huang LM, Quak SH et al. Rotavirus vaccine RIX4414 efficacy sustained during the third year of life: a randomized clinical trial in an Asian population. Vaccine 2012; 30: 4552–7.
20. Payne DC, Boom JA, Staat MA, Edwards KM, Szilagyi PG, Klein EJ et al.Effectiveness of pentavalent and monovalent rotavirus vaccines in concurrent use among US children <5 years of age, 2009-2011. Clin Infect Dis. 2013 Jul;57(1):13-20.
21. Bines JE, Kohl KS, Forster J, Zanardi LR, Davis RL, Hansen J et al. Acute intussusception in infants and children as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation. Vaccine 2004 Jan 26;22(5-6):569-74.
22. Koch J, Harder T, von Kries R, Wichmann O. Risk of Intussusception After Rotavirus Vaccination. Dtsch Arztebl Int. 2017 Apr 14;114(15):255-262.
23. Patel MM, Lopez-Collada VR, Bulhoes MM, De Oliveira LH, Bautista Márquez A, Flannery B et al. Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil. N Engl J Med 2011;364(24):2283-92
24. Carlin JB, Macartney KK, Lee KJ, Quinn HE, Buttery J, Lopert R et al. Intussusception risk and disease prevention associated with rotavirus vaccines in Australia's National Immunization Program. Clin Infect Dis. 2013 Nov;57(10):1427-34
25. Rha B, Tate JE, Weintraub E, Haber P, Yen C, Patel M et al. Intussusception following rotavirus vaccination: an updated review of the available evidence. Expert Rev Vaccines. 2014 Nov;13(11):1339-48.
26. Anderson EJ. Rotavirus vaccines: viral shedding and risk of transmission. The Lancet Infectious Diseases 2008 Oct;8(10):642-9.
27. Van der Wielen M, Van Damme P. Pentavalent human-bovine (WC3) reassortant rotavirus vaccine in special populations: a review of data from the Rotavirus Efficacy and Safety Trial. European Journal of Clinical Microbiology &amp; Infectious Diseases 2008 Jul 1;27(7):495-501.
28. Omeñaca F, Sarlangue J, Szenborn L, Nogueira M, Suryakiran PV, Smolenov IV, Han HH et al. Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European Infants: a randomized phase IIIb study. Pediatr Infect Dis J 2012; 31: 487–93.
29. Steele AD, Madhi SA, Louw CE, Bos P, Tumbo JM, Werner CM et al. Safety, Reactogenicity, and Immunogenicity of Human Rotavirus Vaccine RIX4414 in Human Immunodeficiency Virus-positive Infants in South Africa. The Pediatric Infectious Disease Journal 2011;30(2).